Mucormycosis in India: Pathophysiology and Perspectives on Treatment and Management.
COVID-19
Mucormycosis
black fungus
diabetes
diagnosis
pathogenesis
treatment
Journal
Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
08
2021
revised:
01
12
2021
accepted:
16
12
2021
medline:
10
5
2022
pubmed:
10
5
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
Mucormycosis, also known as "black fungus," is a potentially fatal disorder that causes blurred or double vision, chest pain, and breathing problems. The introduction of novel risk factors and causative agents, as well as the problems with controlling the disease, are all significant problems with mucormycosis in India. It is most common among COVID-19 patients. Mucormycosis is an invasive fungal disease that primarily affects immunosuppressant patients, mainly caused by mold fungi of the genus mucor, rhizopus, rhizomucor, and absidia, which are in the zygomycetes class and the Mucorales order. The most common risk factor is diabetes mellitus, followed by haematological malignancy and solid-organ transplantation. Reversal of underlying predisposing factors, surgical debridement of infected tissues, and proper antifungal therapy are all required for the treatment of mucormycosis. In this review, the epidemiology, pathogenesis, and symptoms of black fungus and its association with covid-19, treatment, and diagnosis are discussed.
Identifiants
pubmed: 35532252
pii: IDDT-EPUB-123194
doi: 10.2174/1871526522666220509064659
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-75Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Hibbett D.S.; Binder M.; Bischoff J.F.; A higher-level phylogenetic classification of the Fungi. Mycol Res 2007,111(Pt 5),509-547
doi: 10.1016/j.mycres.2007.03.004
pubmed: 17572334
Dyer O.; Covid-19: India sees record deaths as “black fungus” spreads fear. BMJ 2021,373(1238),n1238
doi: 10.1136/bmj.n1238
pubmed: 33985993
Ribes J.A.; Vanover-Sams C.L.; Baker D.J.; Zygomycetes in human disease. Clin Microbiol Rev 2000,13(2),236-301
doi: 10.1128/CMR.13.2.236
pubmed: 10756000
Spellberg B.; Edwards J.; Ibrahim A.; Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005,18(3),556-569
doi: 10.1128/CMR.18.3.556-569.2005
pubmed: 16020690
Roden M.M.; Zaoutis T.E.; Buchanan W.L.; Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005,41(5),634-653
doi: 10.1086/432579
pubmed: 16080086
Frater J.L.; Hall G.S.; Procop G.W.; Histologic features of zygomycosis: Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001,125(3),375-378
doi: 10.5858/2001-125-0375-HFOZ
pubmed: 11231486
Jeong W.; Keighley C.; Wolfe R.; The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019,25(1),26-34
doi: 10.1016/j.cmi.2018.07.011
pubmed: 30036666
Reid G.; Lynch J.P.; Fishbein M.C.; Clark N.M.; Mucormycosis. Semin Respir Crit Care Med 2020,41(1),99-114
doi: 10.1055/s-0039-3401992
pubmed: 32000287
Prakash H.; Ghosh A.K.; Rudramurthy S.M.; A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019,57(4),395-402
doi: 10.1093/mmy/myy060
pubmed: 30085158
Patel A.; Kaur H.; Xess I.; A multicentre observational study on the epidemiology, risk factors, management and outcomes of mu-cormycosis in India. Clin Microbiol Infect 2020,26(7),944.e9-944.e15
doi: 10.1016/j.cmi.2019.11.021
pubmed: 31811914
Skiada A.; Pagano L.; Groll A.; Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011,17(12),1859-1867
doi: 10.1111/j.1469-0691.2010.03456.x
pubmed: 21199154
Singh; Kumar, A.; Al., E. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021
Mehta S.; Pandey A.; Rhino-orbital mucormycosis associated with COVID-19. Curesu 2020,12(9),e10726
Chakrabarti A.; Das A.; Sharma A.; Ten years’ experience in zygomycosis at a tertiary care centre in India. J Infect 2001,42(4),261-266
doi: 10.1053/jinf.2001.0831
pubmed: 11545569
Chakrabarti A.; Das A.; Mandal J.; The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006,44(4),335-342
doi: 10.1080/13693780500464930
pubmed: 16772227
Chakrabarti A.; Chatterjee S.S.; Das A.; Invasive zygomycosis in India: Experience in a tertiary care hospital. Postgrad Med J 2009,85(1009),573-581
doi: 10.1136/pgmj.2008.076463
pubmed: 19892892
Manesh A.; Rupali P.; Sullivan M.O.; Mucormycosis-A clinicoepidemiological review of cases over 10 years. Mycoses 2019,62(4),391-398
doi: 10.1111/myc.12897
pubmed: 30685896
Chander J.; Kaur M.; Singla N.; Mucormycosis: Battle with the deadly enemy over a five-year period in India. J Fungi (Basel) 2018,4(2),E46
doi: 10.3390/jof4020046
pubmed: 29642408
Patel A.K.; Patel K.K.; Patel K.; Gohel S.; Chakrabarti A.; Mucormycosis at a tertiary care centre in Gujarat, India. Mycoses 2017,60(6),407-411
doi: 10.1111/myc.12610
pubmed: 28276102
Prakash H.; Chakrabarti A.; Global epidemiology of mucormycosis. J Fungi (Basel) 2019,5(1),E26
doi: 10.3390/jof5010026
pubmed: 30901907
Priya P.; Rajendran T.; Geni V.G.; Mucormycosis in a tertiary care center in South India: A 4-year experience. Indian J Crit Care Med Peer-reviewed, Off Publ Indian Soc. Crit Care Med 2020,24(3),168-171
doi: 10.5005/jp-journals-10071-23387
Prakash H.; Chakrabarti A.; Epidemiology of Mucormycosis in India. Microorganisms 2021,9(3),1-12
doi: 10.3390/microorganisms9030523
pubmed: 33806386
Chakrabarti A.; Kaur H.; Savio J.; Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care 2019,51,64-70
doi: 10.1016/j.jcrc.2019.02.005
pubmed: 30769292
Koffi; David; Al., E. Estimates of serious fungal infection burden in Côte d’Ivoire and Country Health Profile. J Mycol Med 2021,31(1),101086
Sahoo J.P.; Panda S.J.P.; The unseen “Fungal infection”- an extra thrust aggravating covid second wave in India 2021,354-356
Ibrahim A.S.; J. EJ, Edwards Filler, SG. Zygomycosis. In: Clinical mycology 2003,241-251
Ben-Ami R.; Luna M.; Lewis R.E.; Walsh T.J.; Kontoyiannis D.P.; A clinicopathological study of pulmonary mucormycosis in cancer patients: Extensive angioinvasion but limited inflammatory response. J Infect 2009,59(2),134-138
doi: 10.1016/j.jinf.2009.06.002
pubmed: 19576639
Ibrahim A.S.; Spellberg B.; Walsh T.J.; Kontoyiannis D.P.; Pathogenesis of mucormycosis. Clin Infect Dis 2012,54(Suppl. 1),S16-S22
doi: 10.1093/cid/cir865
pubmed: 22247441
Bouchara J.P.; Oumeziane N.A.; Lissitzky J.C.; Larcher G.; Tronchin G.; Chabasse D.; Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol 1996,70(1),76-83
pubmed: 8738422
Ibrahim A.S.; Spellberg B.; Avanessian V.; Fu Y.; Edwards J.E.; Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005,73(2),778-783
doi: 10.1128/IAI.73.2.778-783.2005
pubmed: 15664916
Liu M.; Spellberg B.; Phan Q.T.; The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010,120(6),1914-1924
doi: 10.1172/JCI42164
pubmed: 20484814
Lee A.S.; GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 2007,67(8),3496-3499
doi: 10.1158/0008-5472.CAN-07-0325
pubmed: 17440054
Ni M.; Lee A.S.; ER chaperones in mammalian development and human diseases. FEBS Lett 2007,581(19),3641-3651
doi: 10.1016/j.febslet.2007.04.045
pubmed: 17481612
Li J.; Lee A.S.; Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006,6(1),45-54
doi: 10.2174/156652406775574523
pubmed: 16472112
Wang M.; Wey S.; Zhang Y.; Ye R.; Lee A.S.; Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neuro-logical disorders. Antioxid Redox Signal 2009,11(9),2307-2316
doi: 10.1089/ars.2009.2485
pubmed: 19309259
Chamilos G.; Lewis R.E.; Hu J.; Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008,105(27),9367-9372
doi: 10.1073/pnas.0709578105
pubmed: 18583479
Jeong M.; COVID-19 increases black fungus infection risk in India. 2021. Available from: ,
Gangneux J.P.; Bougnoux M.E.; Dannaoui E.; Cornet M.; Zahar J.R.; Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med 2020,30(2),100971
doi: 10.1016/j.mycmed.2020.100971
pubmed: 32307254
Potenza L.; Vallerini D.; Barozzi P.; Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 2011,118(20),5416-5419
doi: 10.1182/blood-2011-07-366526
pubmed: 21931119
Pasero D.; Sanna S.; Liperi C.; Challenging complication following SARS-CoV-2 infection: A case of pulmonary mucormycosis. Infection 2021,49(5),1055-1060
doi: 10.1007/s15010-020-01561-x
pubmed: 33331988
Pilmis B.; Alanio A.; Lortholary O.; Lanternier F.; Recent advances in the understanding and management of mucormycosis. F1000 Res 2018,7(0),1-8
doi: 10.12688/f1000research.15081.1
pubmed: 30271573
Chamilos G.; Lewis R.E.; Kontoyiannis D.P.; Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008,47(4),503-509
doi: 10.1086/590004
pubmed: 18611163
Prabhu R.M.; Patel R.; Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004,10(Suppl. 1),31-47
doi: 10.1111/j.1470-9465.2004.00843.x
pubmed: 14748801
Skiada A.; Lass-Floerl C.; Klimko N.; Ibrahim A.; Roilides E.; Petrikkos G.; Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018,56(Suppl. 1),93-101
doi: 10.1093/mmy/myx101
pubmed: 29538730
Lass-Flörl C.; Zygomycosis: Conventional laboratory diagnosis. Clin Microbiol Infect 2009,15(Suppl. 5),60-65
doi: 10.1111/j.1469-0691.2009.02999.x
pubmed: 19754760
Monheit J.E.; Cowan D.F.; Moore D.G.; Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med 1984,108(8),616-618
pubmed: 6204621
Millon L.; Herbrecht R.; Grenouillet F.; Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: Retrospective analysis of 44 cases collected through the French surveillance network of invasive fungal infections (RESSIF). Clin Microbiol Infect 2016,22(9),810.e1-810.e8
doi: 10.1016/j.cmi.2015.12.006
pubmed: 26706615
Hsiao C.R.; Huang L.; Bouchara J.P.; Barton R.; Li H.C.; Chang T.C.; Identification of medically important molds by an oligonucleotide array. J Clin Microbiol 2005,43(8),3760-3768
doi: 10.1128/JCM.43.8.3760-3768.2005
pubmed: 16081907
Nagao K.; Ota T.; Tanikawa A.; Genetic identification and detection of human pathogenic Rhizopus species, a major mucormycosis agent, by multiplex PCR based on internal transcribed spacer region of rRNA gene. J Dermatol Sci 2005,39(1),23-31
doi: 10.1016/j.jdermsci.2005.01.010
pubmed: 15978416
J, L.; M, M.; Al, B. K. et. Diagnosis of cutaneous mucormycosis Due to Rhizopus microsporus by an innovative PCR-restriction fragmentlength polymorphism method. Clin Infect Dis 2005,41,1362-1365
doi: 10.1086/497078
Machouart M.; Larché J.; Burton K.; Genetic identification of the main opportunistic mucorales by PCR-restriction fragment length pol-ymorphism. J Clin Microbiol 2006,44(3),805-810
doi: 10.1128/JCM.44.3.805-810.2006
pubmed: 16517858
Nyilasi I, Papp T, Csernetics A. Krizsa’n, K.; E. Nagy1 and C. Va’gvo¨lgyi2; 1Hungarian. High-affinity iron permease (FTR1) gene sequence-based molecular identification of clinically important zygomycetes. Nautilus (Philadelphia) 2015,129(4),175-178
doi: 10.5924/abgri1972.1974.17
Springer J.; Lackner M.; Ensinger C.; Clinical evaluation of a mucorales-specific real-time PCR assay in tissue and serum samples. J Med Microbiol 2016,65(12),1414-1421
doi: 10.1099/jmm.0.000375
pubmed: 27902424
Kasai M.; Harrington S.M.; Francesconi A.; Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008,46(11),3690-3702
doi: 10.1128/JCM.00917-08
pubmed: 18845827
Caillot D.; Valot S.; Lafon I.; Is it time to include CT “Reverse halo sign” and qPCR targeting mucorales in serum to EORTC-MSG crite-ria for the diagnosis of pulmonary mucormycosis in leukemia patients? Open Forum Infect Dis 2016,3(4),ofw190
doi: 10.1093/ofid/ofw190
pubmed: 28101518
Nam B.D.; Kim T.J.; Lee K.S.; Kim T.S.; Han J.; Chung M.J.; Pulmonary mucormycosis: Serial morphologic changes on computed tomography correlate with clinical and pathologic findings. Eur Radiol 2018,28(2),788-795
doi: 10.1007/s00330-017-5007-5
pubmed: 28812135
Legouge C.; Caillot D.; Chrétien M.L.; The reversed halo sign: Pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis 2014,58(5),672-678
doi: 10.1093/cid/cit929
pubmed: 24352351
Farmakiotis D.; Kontoyiannis D.P.; Mucormycoses. Infect Dis Clin North Am 2016,30(1),143-163
doi: 10.1016/j.idc.2015.10.011
pubmed: 26897065
Cornely O.A.; Alastruey-Izquierdo A.; Arenz D.; Global guideline for the diagnosis and management of mucormycosis: An initiative of the European confederation of medical mycology in cooperation with the Mycoses study group education and research consortium. Lancet Infect Dis 2019,19(12),e405-e421
doi: 10.1016/S1473-3099(19)30312-3
pubmed: 31699664
Sabatelli F.; Patel R.; Mann P.A.; In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006,50(6),2009-2015
doi: 10.1128/AAC.00163-06
pubmed: 16723559
Almyroudis N.G.; Sutton D.A.; Fothergill A.W.; Rinaldi M.G.; Kusne S.; In vitro susceptibilities of 217 clinical isolates of zygomycetes to con-ventional and new antifungal agents. Antimicrob Agents Chemother 2007,51(7),2587-2590
doi: 10.1128/AAC.00452-07
pubmed: 17452481
Perkhofer S.; Lechner V.; Lass-Flörl C.; In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the meth-odology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009,53(4),1645-1647
doi: 10.1128/AAC.01530-08
pubmed: 19164153
Chakrabarti Arunaloke; Singh S.; Management of mucormycosis. Curr Fungal Infect Rep 2020,14,348-360
Spanakis E.K.; Aperis G.; Mylonakis E.; New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Clin Infect Dis 2006,43(8),1060-1068
doi: 10.1086/507891
pubmed: 16983621
Sun Q.N.; Fothergill A.W.; McCarthy D.I.; Rinaldi M.G.; Graybill J.R.; In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002,46(5),1581-1582
doi: 10.1128/AAC.46.5.1581-1582.2002
pubmed: 11959605
Thompson G.R.; Wiederhold N.P.; Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010,170(5),291-313
doi: 10.1007/s11046-010-9324-3
pubmed: 20524153
Arendrup M.C.; Jensen R.H.; Meletiadis J.; In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother 2015,59(12),7735-7742
doi: 10.1128/AAC.01919-15
pubmed: 26438494
Ashley, Dodds E, Perfect. J R. Pharmacology of azoles. UpToDate. Kauffman Waltham, MA 2017
Nithyanandam S.; Jacob M.S.; Battu R.R.; Thomas M.S.; Correa M.A.; D’Souza O.; Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003,51,231-236
Kontoyiannis D.P.; Wessel V.C.; Bodey G.P.; Rolston K.V.I.; Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000,30(6),851-856
doi: 10.1086/313803
pubmed: 10852735
Asai K.; Suzuki K.; Takahashi T.; Ito Y.; Kazui T.; Kita Y.; Pulmonary resection with chest wall removal and reconstruction for invasive pul-monary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg 2003,51(4),163-166
doi: 10.1007/s11748-003-0055-y
pubmed: 12723589
Sun H.Y.; Aguado J.M.; Bonatti H.; Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009,9(9),2166-2171
Sun H.Y.; Forrest G.; Gupta K.L.; Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010,90(1),85-92
doi: 10.1097/TP.0b013e3181dde8fc
pubmed: 20626095
Lee F.Y.; Mossad S.B.; Adal K.A.; Pulmonary mucormycosis: The last 30 years. Arch Intern Med 1999,159(12),1301-1309
doi: 10.1001/archinte.159.12.1301
pubmed: 10386506
Gil-Lamaignere C.; Simitsopoulou M.; Roilides E.; Maloukou A.; Winn R.M.; Walsh T.J.; Interferon- γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005,191(7),1180-1187
doi: 10.1086/428503
pubmed: 15747255
Roilides E.; Antachopoulos C.; Simitsopoulou M.; Pathogenesis and host defence against mucorales: The role of cytokines and interaction with antifungal drugs. Mycoses 2014,57(Suppl. 3),40-47
doi: 10.1111/myc.12236
pubmed: 25175306
Grimaldi D.; Pradier O.; Hotchkiss R.S.; Vincent J.L.; Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis 2017,17(1),18
doi: 10.1016/S1473-3099(16)30541-2
pubmed: 27998559